Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cancer|Solid Tumor
Interventions: DRUG: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Sponsor: NewLink Genetics Corporation